Growplex is committed to research and development, working together with partners to enable our dedicated research programme.
The aim of our programme is to help patients improve their quality of life through world-class medicinal products. The creation of a GMP-certified growing operation will allow Growplex to cultivate and manufacture cannabis consistently to medical grade.
Research and Development
Arthritis is the second most dominant health issue and currently affects 500K New Zealanders and 54M (23%) of adults in the US. More than half of New Zealanders will be affected by arthritis at some point in their life.
Chronic pain is a serious condition that affects one in six (16.9%) New Zealanders. Globally, over 1.5 billion people suffer from chronic pain and it’s considered the number one cause of long-term disability in the US.
Cancer rates in New Zealand are the fourth-highest in the world with over 20,000 people diagnosed annually. 14 million people are diagnosed with cancer every year and this is expected to rise by 70% in just two years.
The World Health Organization reports that neurological disorders ranging from epilepsy to Parkinson’s disease, affect up to 1 billion people worldwide. Trends indicate the greatest impact will be on high-income countries like NZ.
We are working with Callaghan Innovation and number of supporting industry partners
developing our Growplex Medicinal Cannabis Research and Development plan.
For more information on how to make the most of this see here: